Abstract:Anaplastic thyroid cancer (ATC) is a rare, fatal cancer with a five-year survival of 4%. Universally diagnosed at stage IV, ATC is characterized by its lack of differentiation and metabolic dysregulation. Refractory to all established therapies, we propose natural alkaloid berberine (BBR) as a therapeutic with multitarget efficacy to alter mitochondrial metabolism and reprogram ATC's aggressive phenotype. Assays used monocyte cell line U937, ATC cell lines T238 and SW1736, and immortalized normal thyroid cell line Nthy-ori-3-1. All assays used 100μM concentration of BBR or DMSO vehicle control for 24 hours for a tumoricidal effect. Validation of in vitro findings via RNA-Seq was conducted by Genewiz from Azenta and Qiagen's Ingenuity Pathway Analysis was used for in silico modeling. Mitochondria were isolated via differential centrifugation. Modeling the ATC tumor microenvironment, U937 cells were activated and polarized into a proinflammatory macrophage phenotype. BBR treatment at the activation/polarization stages, 33 soluble inflammatory mediators were downregulated in the conditioned media compared to controls. In targeting the aggressiveness of anaplastic thyroid disease, BBR slowed proliferation by 80% selectively in ATC cells from 48 to 72 hours, while sparing normal cells. BBR reduced migratory capacity by 30% in ATC cells after 24, 48, and 72 hours and reduced migration and invasion by 30%. These observations were substantiated by Western blot analysis - BBR selectively decreased phosphorylation of MEK, ERK, and ribosomal protein S6, crucial downstream regulators of the pro-proliferative and pro-survival pathways in ATC cells. Further, BBR specifically modulated cancer-associated metabolism as observed through an increase in AMPKα phosphorylation, a major rate-limiting protein in cancer-induced dysregulation with an anti-tumor effect. Validation of in vitro findings via RNA-Seq revealed more than 400 significantly differentially expressed genes involved in mitochondrial metabolism, glycometabolism, sirtuin signaling, apoptosis, and proliferation. Following a comprehensive analysis, we identified significant downregulation of 25 of 37 total mitochondrially encoded genes (MTs) and 13 of 13 mitochondrially encoded protein-coding genes comprising the oxidative phosphorylation complexes illuminating a clear link between BBR treatment and altered mitochondrial metabolism in ATC. Additionally, protein expression of significantly downregulated mitochondrial genes identified via RNA Seq was validated via Western blot demonstrating decreased mitochondrially-encoded protein expression related to oxidative phosphorylation. This work reveals a novel role for BBR as an inhibitor of mitochondrial metabolism that can be used to reprogram the aggressive nature of ATC and open the door for promising combination therapy in the treatment of ATC. Citation Format: Tara Jarboe, Nicole R. DeSouza, Kaci Kopec, Jan Geliebter, Xiu-Min Li, Raj K. Tiwari. Remodeling of anaplastic thyroid cancer metabolic signature by natural alkaloid berberine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7059.

Abstract 864: Novel synthetic berbamine derivatives inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells

Novel Synthetic Berbamine Derivatives Inhibit Jak2/Stat3 Signaling And Induce Apoptosis Of Human Melanoma Cells

Novel Synthetic Derivatives of the Natural Product Berbamine Inhibit Jak2/Stat3 Signaling and Induce Apoptosis of Human Melanoma Cells.

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

The Antiproliferation Effect of Berbamine on K562 Resistant Cells by Inhibiting NF‐κB Pathway

[Effects of Berbamine on K562 Cells and Its Mechanisms in Vitro and in Vivo].

4-Chlorbenzoyl Berbamine, a Novel Derivative of the Natural Product Berbamine, Potently Inhibits the Growth of Human Myeloma Cells by Modulating the NF-κB and JNK Signalling Pathways

4-Chlorobenzoyl Berbamine, a Novel Berbamine Derivative, Induces Apoptosis in Multiple Myeloma Cells Through the IL-6 Signal Transduction Pathway and Increases FOXO3a-Bim Expression.

[Berbamine induces apoptosis of multiple myeloma RPMI 8226 cells by activating GADD45/JNK pathway].

Berbamine Selectively Induces Apoptosis of Human Acute Promyelocytic Leukemia Cells Via Survivin-Mediated Pathway

4-Chlorobenzoyl Berbamine Induces Apoptosis And G2/M Cell Cycle Arrest Through The Pi3k/Akt And Nf-Kappa B Signal Pathway In Lymphoma Cells

Novel Synthetic 4-Chlorobenzoyl Berbamine Inhibits C-Myc Expression and Induces Apoptosis of Diffuse Large B Cell Lymphoma Cells.

Berbamine, a Novel Nuclear Factor Κb Inhibitor, Inhibits Growth and Induces Apoptosis in Human Myeloma Cells

Abstract 3567: the Antitumor Agent OSW-1 in Melanoma Therapy : an Insight

Abstract 872: Novel Potent and Orally Active STAT3 Inhibitors for Cancer Therapies.

Abstract B63: Developing Novel STAT3 Inhibitors for the Treatment and Prevention of Cancer

A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway

Abstract 1034: A natural inhibitor of c-Jun N-terminal kinase 1

Abstract 7059: Remodeling of anaplastic thyroid cancer metabolic signature by natural alkaloid berberine

Discovery and Evaluation of Atopaxar Hydrobromide, a Novel JAK1 and JAK2 Inhibitor, Selectively Induces Apoptosis of Cancer Cells with Constitutively Activated STAT3

Abstract 2564: High-throughput siRNA library screen for discovery and identification of new melanoma therapeutic targets in combination with antioxidant pretreatment